Last updated on May 2018

A Study to Investigate BAY2402234 a Dihydroorotate Dehydrogenase (DHODH) Inhibitor in Myeloid Malignancies


Brief description of study

To determine the safety, tolerability, pharmacokinetics, maximum tolerated dose, or pharmacological active dose of BAY2402234 in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML)

Clinical Study Identifier: NCT03404726

Contact Investigators or Research Sites near you

Start Over

Bayer Clinical Trials Contact

Albert Einstein College of Medicine
Bronx, NY United States
  Connect »

Bayer Clinical Trials Contact

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »

Bayer Clinical Trials Contact

Thomas Jefferson University
Philadelphia, PA United States
  Connect »

Bayer Clinical Trials Contact

Vanderbilt University Medical Center
Nashville, TN United States
  Connect »

Bayer Clinical Trials Contact

Institut Gustave Roussy - Villejuif
Villejuif Cedex, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.